Your session is about to expire
← Back to Search
iC9/CAR.19/IL15-Transduced CB-NK Cells for B-Cell Lymphoma
Study Summary
This trial is for people with B-cell lymphoma or leukemia who have relapsed or are refractory to treatment. The study will test if giving CAR-NK cells after chemotherapy will improve the disease.
- B-Cell Lymphoma
- Acute Lymphoblastic Leukemia
- Chronic Lymphocytic Leukemia
- Non-Hodgkin's Lymphoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are participants actively being added to this investigation?
"Despite initial posting in June 21st 2017, the information on clinicaltrials.gov shows that this specific trial is no longer enlisting patients. Nevertheless, there are over 5000 other studies actively researching new recruits at present."
In what ways is iC9/CAR.19/IL15-Transduced CB-NK Cells being utilized therapeutically?
"iC9/CAR.19/IL15-Transduced CB-NK Cells are a viable therapeutic option for multiple sclerosis, Acute Leukemia, Myelocytic Leukemia and Retinoblastoma."
Does the age criterion for this research protocol include individuals under 45 years of age?
"To be included in this study, patients must meet the age requirement of between 7 to 80 years old. There are 1110 studies available for those younger than 18 and 4370 studies open to seniors 65 and over."
To whom is this test protocol open?
"This clinical trial seeks 36 individuals with chronic B-cell leukemia, lymphocytic leukemia and other related conditions between the ages of 7 to 80. Applicants must be 3 weeks removed from their last cytotoxic chemotherapy session before beginning lymphodepleting chemotherapy, as well as maintain a Karnofsky/Lansky Performance Scale score higher than 70. Furthermore, all participants who are able to have children must practice adequate contraception for the duration of the study; males should use condoms with spermicide or abstain while females can opt for hormonal birth control methods such as intrauterine devices or diaphragms with spermicides."
What is the uppermost limit for participation in this experiment?
"This clinical trial is not currently enrolling participants. It was first posted on June 21st 2017, and the last update was August 1st 2022. If you are searching for alternative studies, there are 4170 trials recruiting patients with leukemia, lymphocytic/chronic B-cell, as well as 924 trails seeking iC9/CAR 19/IL15 Transduced CB-NK Cells patient participation."
Are there any previous reports of iC9/CAR.19/IL15-Transduced CB-NK Cells being used for research purposes?
"Currently, there are 161 Phase 3 clinical trials and 924 live studies for iC9/CAR.19/IL15-Transduced CB-NK Cells scattered across 28576 locations in the United States with Philadelphia being a major research hub."
Share this study with friends
Copy Link
Messenger